ProCE Banner Activity

Targeted Therapy for Indolent Lymphomas: Where We Are and Where We Are Heading

Clinical Thought
How do recent advances in targeted therapies affect patients with less common forms of indolent non-Hodgkin’s lymphoma?

Released: May 26, 2015

Expiration: May 24, 2016

No longer available for credit.

Share

Faculty

Steven M. Horwitz

Steven M. Horwitz, MD

Assistant Attending Physician, Lymphoma Service
Department of Medicine
Memorial Sloan-Kettering Cancer Center
New York, New York

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Gilead

Faculty Disclosure

Primary Author

Steven M. Horwitz, MD

Assistant Attending Physician, Lymphoma Service
Department of Medicine
Memorial Sloan-Kettering Cancer Center
New York, New York

Steven M. Horwitz, MD, has disclosed that he has received consulting fees from Amgen, Bristol-Myers Squibb, Celgene, Janssen, Millennium, Seattle Genetics, and Spectrum and funds for research support from Celgene, Infinity, Kyowa Hakko Kirin, Millennium, Seattle Genetics, and Spectrum.